Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2004-12-29
2009-12-22
Nickol, Gary B (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C435S069100, C435S069500, C435S069700
Reexamination Certificate
active
07635754
ABSTRACT:
Chimeric polypeptide antagonists that include an interleukin-4 (IL-4) mutein linked to an interleukin-9 (IL-9) mutein are provided, as are polynucleotides encoding the IL-4 and IL-9 chimeric mutein antagonists. Also provided are methods of using the chimeric mutein antagonists and encoding polypeptides to reduce or inhibit the responsiveness of a cell to a cytokine such as IL-4, IL-9 and/or interleukin-13. Methods using the compositions to treat disorders such as pulmonary disorders (e.g., asthma) also are provided.
REFERENCES:
patent: 5011912 (1991-04-01), Hopp et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5314695 (1994-05-01), Brown
patent: 5395619 (1995-03-01), Zalipsky et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5723118 (1998-03-01), Sebald
patent: 5882679 (1999-03-01), Needham
patent: 6130318 (2000-10-01), Wild et al.
patent: 6770745 (2004-08-01), Burkly et al.
patent: 2004/0259768 (2004-12-01), Lauermann
patent: WO 2004/103295 (2004-02-01), None
patent: WO 2004/021861 (2004-03-01), None
patent: WO 2004/021861 (2004-03-01), None
patent: WO 2004/103295 (2004-12-01), None
LaPorte et al., PNAS, 2005, 102(6):1889-1894.
Wang et al., Annu. Rev. Biophys. Biomol. Struct., 2006, 35:225-249 (abstract).
Anderson, W. French, “Human Gene Therapy,”Nature, vol. 392, Supplement, pp. 25-30, 1998.
Dong, Qu et al., “IL-9 Induces Chemokine Expression in Lung Epithelial Cells and Baseline Airway Eosinophilia in Transgenic Mice”,Eur. J. Immunol. vol. 29, pp. 2130-2139, 1999.
Ecker and Crooke, “Combinatorial Drug Discovery: Which Methods Will Produce the Greatest Value?”Biotechnology, vol. 13, pp. 351-360, 1995.
Expert Panel on the Management of Asthma, “Definition and Diagnosis,”The Journal of Allergy and Clinical Immunology, vol. 88, No. 3, Part 2, pp. 425-438, Sep. 1991.
Flotte, Terence R., “Prospects for Virus-Based Gene Therapy for Cystic Fibrosis,”Journal of Bioenergetics and Biomembranes, vol. 25, No. 1, pp. 37-42, 1993.
Fraley and Papahadjopoulos, “New Generation Liposomes: The Engineering of an Efficient Vehicle for Intracellular Delivery of Nucleic Acids,”TIBS, pp. 77-80, Mar. 1981.
Goeddel, David, V., “Systems for Heterologous Gene Expression,”Methods in Enzymology, vol. 185, pp. 3-7, 1990.
Henderson, William R. Jr., Soluble IL-4 Receptor Inhibits Airway Inflammation Following Allergen Challenge in a Mouse Model of Asthma1,J. Immunol., vol. 164, pp. 1086-1095, 2000.
Hopp, Thomas P. et al, “A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification”,BioTechnology, vol. 6, pp. 1204-1210, 1988.
Huang, Shau-Ku et al., IL-13 Expression at the Sites of Allergen Challenge in Patients with Asthma,J. Immunol., vol. 155, pp. 2688-2694, 1995.
Jellinek et al., “Potent 2′-Amino-2′-deoxypyrimidine RNA Inhibitors of Basic Fibroblast Growth Factor”,Biochemistry, vol. 34, pp. 11363-11372, 1995.
Jolly, Douglas, “Viral Vector Systems for Gene Therapy,”Cancer Gene Therapy, vol. 1, No. 1, pp. 51-64, 1994.
Krishenbaum et al., “Highly Efficient Gene Transfer into Adult Ventricular Myocytes by Recombinant Adenovirus,”Journal of Clinical Investigation, vol. 92, pp. 381-387, 1993.
Lin et al., “Modified RNA Sequence Pools for in vitro Selection,”Nucleic Acids Research, vol. 22, No. 24, pp. 5229-5234, 1994.
Longphre, M. et al., “Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells”,J. Clin. Invest, vol. 104, pp. 1375-1382, 1999.
Michael et al., “Binding-incompetent Adenovirus Facilities Molecular Conjugate-Mediated Gene Transfer by the Receptor-Mediated Endocytosis Pathway,”The Journal of Biological Chemistry, vol. 268, No. 10, pp. 6866-6869, 1993.
Miller and Rosman, “Improved Retroviral Vectors for Gene Transfer and Expression,”Biotechniques, vol. 7, No. 9, pp. 980-990, 1989.
Morishita et al., “Novel and Effective Gene Transfer Technique for Study of Vascular Renin Angiotensin System,”Journal of Clinical Investigation, vol. 91, pp. 2580-2585, 1993.
O'Byrne and Inman, “Airway Hyperresponsiveness,”Chest, vol. 123, No. 3, pp. 411S-416S, Mar. 2003.
Pagratis et al., “Potent 2′-amino-, and 2′-Fluoro-2′-Deoxyribonucleotide RNA Inhibitors of Keratinocyte Growth Factor,”Nature Biotechnology, vol. 15, pp. 68-73, Jan. 1997.
Postma et al., “Genetic Susceptibility to Asthma—Bronchial Hyperresponsiveness Coinherited with a Major Gene for Atopy,”The New England Journal of Medicine, vol. 333, pp. 894-900, 1995.
Tam et al., “Biological Availability and Nuclease Resistance Extend the in vitro activity of a phosphorothioate-3′hydroxypropylamine Oligonucleotide,”Nucleic Acids Research, vol. 22, No. 6, pp. 977-986, 1994.
Ulbrecht et al., “High Serum IgE Concentrations: Association with HLA-DR and Markers on Chromosome 5q31 and Chromosome 11q13,”Journal of Allergy and Clinical Immunology, vol. 99, pp. 828-836, 1997.
Verma and Somia, “Gene Therapy-Promises, Problems and Prospects,”Nature, vol. 389, pp. 239-242, Sep. 18, 1997.
Wilson, James M., “Adenoviruses as Gene-Delivery Vehicles,”Molecular Medicine, vol. 334, No. 18, pp. 1185-1187, 1996.
Ying et al., “Expression of IL-4 and IL-5 mRNA and Protein Product by CD4+and CD8+T Cells, Eosinophils, and Mast Cells in Bronchial Biopsies Obtained from Atopic and Nonatopic (Intrinsic) Asthmatics,”The Journal of Immunology, vol. 158, pp. 3539-3544, 1997.
Zhu et al., “Pulmonary Expression of Interleukin-13 Causes Inflammation, Mucus Hypersecretion, Subepithelial, Fibrosis, Pysiologic Abnormalities, and Eotaxin Production,”The Journal of Clinical Investigation, vol. 103, No. 6, pp. 779-788, Mar. 1999.
Boisvert David C.
Longphre Malinda
Wong Teresa M.
Zaremba Sydney M.
Aerovance, Inc.
DLA Piper (LLP) US
Nickol Gary B
Xie Xiaozhen
LandOfFree
Interleukin-9 and interleukin-4 chimeric antagonist muteins... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-9 and interleukin-4 chimeric antagonist muteins..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-9 and interleukin-4 chimeric antagonist muteins... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4129621